Akamis Bio Revenue and Competitors
Estimated Revenue & Valuation
- Akamis Bio's estimated annual revenue is currently $7.9M per year.
- Akamis Bio's estimated revenue per employee is $155,000
- Akamis Bio's total funding is $185M.
Employee Data
- Akamis Bio has 51 Employees.
- Akamis Bio grew their employee count by -30% last year.
Akamis Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Head People and Culture | Reveal Email/Phone |
3 | Facilities Officer | Reveal Email/Phone |
4 | SVP, Head Research | Reveal Email/Phone |
5 | Director Chemistry, Manufacturing & Controls (CMC) | Reveal Email/Phone |
6 | Director, Facilities and IT | Reveal Email/Phone |
7 | Director, Group Controller | Reveal Email/Phone |
8 | Associate Clinical Study Manager | Reveal Email/Phone |
9 | Senior Supply Chain Manager | Reveal Email/Phone |
10 | Sr. Clinical Trial Manager | Reveal Email/Phone |
Akamis Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 35 | -12% | N/A | N/A |
#2 | $16.3M | 105 | 4% | N/A | N/A |
#3 | $107.2M | 494 | 25% | $292M | N/A |
#4 | $2.6M | 830 | 30% | $631.7M | N/A |
#5 | $18.1M | 117 | -8% | $81M | N/A |
#6 | $1.2M | 271 | 12% | $440M | N/A |
#7 | $54.6M | 282 | 0% | $132.9M | N/A |
#8 | $9.3M | 60 | -37% | N/A | N/A |
#9 | $21.2M | 137 | 12% | N/A | N/A |
#10 | $408.2M | 1646 | 11% | £994.6M | N/A |
What Is Akamis Bio?
Akamis is a clinical-stage oncology company whose mission is to leverage its groundbreaking T-SIGn® platform to positively impact the lives of people living with cancer. We are developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. Akamis’ growing pipeline of T-SIGn® therapeutics is anchored by its lead clinical-stage program, NG-350A, which is being investigated in an ongoing Phase 1 clinical study in patients with metastatic or advanced epithelial tumors. Akamis has a number of T-SIGn® platform-focused collaborations with leaders in the immuno-oncology field including BMS, Merck, and the Parker Institute for Cancer Immunotherapy (PICI) To learn more, please visit www.akamisbio.com.
keywords:N/A
$185M
Total Funding
51
Number of Employees
$7.9M
Revenue (est)
-30%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Abingdon
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.1M | 52 | -7% | N/A |
#2 | $6M | 56 | 8% | N/A |
#3 | $17.2M | 58 | -9% | N/A |
#4 | $5.3M | 59 | 7% | N/A |
#5 | $9.3M | 60 | -9% | N/A |